Format

Send to

Choose Destination
Invest Ophthalmol Vis Sci. 2017 Jun 1;58(7):3031-3043. doi: 10.1167/iovs.16-20913.

Binocular Therapy for Childhood Amblyopia Improves Vision Without Breaking Interocular Suppression.

Author information

1
UCL Institute of Ophthalmology, University College London, London, United Kingdom.
2
National Institute for Health Research Biomedical Research Centre at Moorfields Eye Hospital and UCL Institute of Ophthalmology, London, United Kingdom.
3
UCL Institute of Ophthalmology, University College London, London, United Kingdom 3UCL Institute of Cognitive Neuroscience, University College London, London, United Kingdom.
4
Department of Psychology, Northeastern University, Boston, Massachusetts, United States.
5
Experimental Psychology, University College London, London, United Kingdom.
6
UCL Institute of Ophthalmology, University College London, London, United Kingdom 2National Institute for Health Research Biomedical Research Centre at Moorfields Eye Hospital and UCL Institute of Ophthalmology, London, United Kingdom 6School of Optometry and Vision Science, University of Auckland, Auckland, New Zealand.

Abstract

Purpose:

Amblyopia is a common developmental visual impairment characterized by a substantial difference in acuity between the two eyes. Current monocular treatments, which promote use of the affected eye by occluding or blurring the fellow eye, improve acuity, but are hindered by poor compliance. Recently developed binocular treatments can produce rapid gains in visual function, thought to be as a result of reduced interocular suppression. We set out to develop an effective home-based binocular treatment system for amblyopia that would engage high levels of compliance but that would also allow us to assess the role of suppression in children's response to binocular treatment.

Methods:

Balanced binocular viewing therapy (BBV) involves daily viewing of dichoptic movies (with "visibility" matched across the two eyes) and gameplay (to monitor compliance and suppression). Twenty-two children (3-11 years) with anisometropic (n = 7; group 1) and strabismic or combined mechanism amblyopia (group 2; n = 6 and 9, respectively) completed the study. Groups 1 and 2 were treated for a maximum of 8 or 24 weeks, respectively.

Results:

The treatment elicited high levels of compliance (on average, 89.4% ± 24.2% of daily dose in 68.23% ± 12.2% of days on treatment) and led to a mean improvement in acuity of 0.27 logMAR (SD 0.22) for the amblyopic eye. Importantly, acuity gains were not correlated with a reduction in suppression.

Conclusions:

BBV is a binocular treatment for amblyopia that can be self-administered at home (with remote monitoring), producing rapid and substantial benefits that cannot be solely mediated by a reduction in interocular suppression.

PMID:
28614556
DOI:
10.1167/iovs.16-20913
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Silverchair Information Systems
Loading ...
Support Center